Clinical Trials Sponsored by Jiangsu Topcel-KH Pharmaceutical Co., Ltd

Total 322 results

Hunan Cancer Hospital
Jiangsu Hengrui Pharmaceuticals Co.,Ltd

Recruiting

A Study of Camrelizumab Combined Apatinib in Hepatocellular Carcinoma Previously Treated With Immune Checkpoint Inhibitors (ICIs).

Hepatocellular Carcinoma | Immune Checkpoint Inhibitors

China
Fujian Cancer Hospital
Jiangsu Hengrui Pharmaceutical Co., Ltd.; SunWay Biotech Co., LTD.

Not yet recruiting

Recombinant Human Adenovirus Type 5 Injection Combined With PD-1 Monoclonal Antibody and Nab-paclitaxel in the Treatment of Patients With Liver Metastases From Malignant Melanoma

Liver Metastases | Malignant Melanoma
Beijing Immunochina Medical Science & Technology...
Jiangsu Simcere Pharmaceutical Co., Ltd.

Recruiting

Assessment of Safety and Efficacy of IM19 for Recurrent or Refractory (R/R) Non-Hodgkin's Lymphoma(NHL) Patients

NHL

China
Sun Yat-sen University
Jiangsu Hengrui Pharmaceutical Co., Ltd.

Recruiting

Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response

Nasopharyngeal Carcinoma

China
Sun Yat-sen University
Jiangsu Hengrui Pharmaceutical Co., Ltd.

Not yet recruiting

A Phase Ib/II Clinical Study of Camrelizumab and Apatinib Plus GP in the Treatment of Advanced Biliary Tract Cancer

Metastatic Biliary Tract Cancer | Locally Advanced Biliary Tract Cancer

China
Zhongshan Hospital Xiamen University
Jiangsu Hengrui Pharmaceutical Co., Ltd.

Not yet recruiting

Camrelizumab Combined With Intraperitoneal Infusion of Nab-paclitaxel, Intravenous Chemotherapy and S-1 in the Treatment of Advanced Gastric Cancer With Peritoneal Metastasis：Single-arm, Prospective Clinical Study

Stage IV Gastric Cancer With Metastasis
Wuhan Union Hospital, China
Jiangsu Hengrui Pharmaceutical Co., Ltd.

Not yet recruiting

Efficacy and Safety of TPO Receptor Agonists in the Treatment of Elderly ITP Patients

Primary Immune Thrombocytopenia
Peking University People's Hospital
Jiangsu Hengrui Pharmaceutical Co., Ltd.

Enrolling by invitation

Neoadjuvant Fluzoparib Combined With Camrelizumab in Germline BRCA-mutated HER2-negative Breast Cancer

Germline BRCA-mutated HER2-negative Breast Cancer

China
Jiangsu Simcere Pharmaceutical Co., Ltd.
Shanghai Xianxiang Medical Technology Co., Ltd.; Simcere Zaiming

Recruiting

A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0237 in Adult Participants With Advanced Solid Tumors

Locally Advanced Unresectable or Metastatic Solid Tumor

United States, China
Sun Yat-sen University
JIANGSU JIBEIER PHARMACEUTICAL CO.,LTD

Not yet recruiting

A Multi-center, Randomized, Double-blind, Phase III Clinical Trial of Leucogen Versus Placebo on Leukocyte and Platelet Whole-course Management Assisted by PFLL Chemotherapy in the Treatment of Stage IV, Recurrent or Metastatic NPC

Nasopharyngeal Carcinoma | Chemotherapy | Myelosuppression | Leucogen

China
Wuhan Union Hospital, China
Jiangsu Hengrui Pharmaceutical Co., Ltd.

Not yet recruiting

An Observational, Multicenter Study to Evaluate the Safety and Effectiveness of Hetrombopag in Patients With ITP or AA

Aplastic Anemia | Primary Immune Thrombocytopenia

China
Jiangsu Kanion Pharmaceutical Co., Ltd
Shanghai Mental Health Center

Not yet recruiting

Evaluate the Safety, Tolerability and Pharmacokinetic Profile of TPN672 Tablets Maleate in Patients With Schizophrenia (TPN672)

Schizophrenia

China
Suzhou Kintor Pharmaceutical Inc,
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Recruiting

A Phase Ib/II Study of GT90001 Combined With KN046 in Solid Tumors

Solid Tumor

Taiwan
Sun Yat-sen University
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Unknown

Olanzapine Plus Fosaprepitant Standard Antiemetic Therapy in the Prevention of Chemotherapy-induced Nausea and Vomiting in Patients Receiving High Emetic Risk Multi-day Chemotherapy: a Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study (OFFER)

Solid Tumor Patients Receiving High Emetic Risk Multi-day Chemotherapy

China
Sun Yat-sen University
Jiangsu Hengrui Pharmaceutical Co., Ltd.

Recruiting

Phase Ib/II Study of Fluzoparib in Combination With Dalpiciclib in Patients With Locally Advanced or Metastatic Sarcoma

Sarcoma

China
Sichuan Provincial People's Hospital
Jiangsu Simcere Pharmaceutical Co., Ltd.

Unknown

Recombinant Human Endostatin in Combination With XELOX Therapy in Patient With Advanced Colorectal Cancer. (EXECC)

Quality of Life

China
Shanghai Mental Health Center
Jiangsu Nhwa Pharmaceutical Co., Ltd.

Completed

A Clinical Trial to Evaluate the Efficacy and Safety of Generic Escitalopram in Depression

Depression

China
Shanghai Mental Health Center
Jiangsu Nhwa Pharmaceutical Co., Ltd.

Completed

A Study to Evaluate the Pharmacokinetics of Duloxetine in Chinese Han Healthy Subjects

Healthy

China
Jiangxi Qingfeng Pharmaceutical Co. Ltd.
Shanghai De Novo Pharmatech Co., Ltd.

Unknown

Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Healthy Volunteers

Advanced Solid Tumors

China
Peking Union Medical College Hospital
Dizal (Jiangsu) Pharmaceutical Co., Ltd.

Recruiting

Assessing an Oral EGFR Inhibitor, DZD9008 in Patients With Advanced Non-small Cell Lung Cancer(NSCLC) With EGFR Mutations (WU-KONG15) (WU-KONG15)

Non Small Cell Lung Cancer

China
Guangdong Association of Clinical Trials
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Recruiting

MRD Guiding Treatment After Almonertinib Induction Therapy for EGFRm+ Stage III NSCLC in the MDT Diagnostic Model. (APPROACH)

Lung Cancer

China
Peking University Cancer Hospital & Institute
Jiangsu Hengrui Pharmaceutical Co., Ltd.

Not yet recruiting

Evaluation Effectiveness and Safety of (cTACE or DEB-TACE + FOLFOX Regimen HAIC) Combined With Camrelizumab and Apatinib Mesylas in the Treatment of Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma
Chinese PLA General Hospital
Jiangsu Suzhong Pharmaceutical Group Co., Ltd.

Unknown

Efficacy and Safety of Abelmoschus Manihot for Chronic Kidney Disease

Chronic Kidney Disease

China
Baohui Han
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Recruiting

Aumolertinib Adjuvant Therapy of Resectable Stage I EGFRm+ NSCLC With High-grade Patterns (APPOINT)

Lung Cancer

China
Peking University First Hospital
Jiangsu Wanbang Pharmaceutical Marketing Co.,Ltd.

Unknown

Efficacy of Dun Ye Guan Xin Ning Tablet in Patients With Stable Angina Pectoris

Coronary Heart Disease

China
Zhejiang University
Beta Pharma, Inc.; Jiangsu Simcere Pharmaceutical Co., Ltd.

Unknown

Rh-Endostatin in Combination With Icotinib for Advanced NSCLC With EGFR Mutations

Lung Cancer

China
Jiangsu Kanion Pharmaceutical Co., Ltd
Beijing University of Chinese Medicine

Unknown

A Clinical Trial To Evaluate Reduning Injection in the Treatment of Mild Type of Hand, Foot, and Mouth Disease

Hand, Foot and Mouth Disease

China
Asieris Pharmaceuticals (AUS) Pty Ltd.

Completed

A Phase I, Two-phase, Crossover Study to Evaluate the Safety, Tolerability and Pharmacokinetics of APL-1501 ER Tablets

Bladder Cancer

Australia
Wuhan Union Hospital, China
Jiangsu HengRui Medicine Co., Ltd.; CSPC ZhongQi Pharmaceutical Technology...

Not yet recruiting

Camrelizumab in Combination With PLD and Losartan in Patients With TNBC Who Have Received ≦ 1 Line of Chemotherapy

Breast Cancer

China
Xiangya Hospital of Central South University
Jiangsu Simcere Pharmaceutical Co., Ltd.

Not yet recruiting

Effect of Early Versus Late Initiation of Edaravone Dexborneol on Neural Function in Patients With Acute Ischemic Stroke (EARLYS)

Ischemic Stroke, Acute | Treatment Outcome

China
Nanfang Hospital of Southern Medical University
Jiangsu Simcere Pharmaceutical Co., Ltd.

Not yet recruiting

Iguratimod Combined With Tofacitinib in the Treatment of Rheumatoid Arthritis

Rheumatoid Arthritis
Jiangsu Simcere Pharmaceutical Co., Ltd.
Second Hospital of Shanxi Medical University

Completed

A Pilot Bioequivalence Study of Pomalidomide

Bioequivalence

China
First Affiliated Hospital of Zhejiang University
Jiangsu Aosaikang Pharmaceutical Co., Ltd.

Completed

A Clinical Trial to Evaluate the Safety and Tolerability of Dexlansoprazole Injection in Healthy Chinese Adults (Part 1)

Safety Issues
Second Affiliated Hospital of Nanchang University
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Not yet recruiting

Almonertinib With Bevacizumab for EGFR-Mutant NSCLC Patients With Leptomeningeal Metastasis (ATTRACT)

NSCLC | EGFR Activating Mutation | Leptomeningeal Metastasis

China
Jiangsu Simcere Pharmaceutical Co., Ltd.
The First People's Hospital of Lianyungang

Unknown

Continuous Endostar Infusion Combined With Radiotherapy in Esophageal Cancer Patients

Esophageal Cancer

China
Nanfang Hospital of Southern Medical University
Jiangsu Hengrui Pharmaceutical Co., Ltd.

Recruiting

Adjuvant Chemotherapy Combined With Camrelizumab for ⅡA -ⅢA NSCLC Patients (PANORAMA)

Chemotherapy | Immunotherapy

China
The Central Hospital of Lishui City
Jiangsu Hengrui Pharmaceutical Co., Ltd.

Recruiting

Safety Evaluation of Linear and Macrocyclic Gadolinium Based Contrast Agents for Patients With Mild to Moderate Renal Insufficiency Undergoing Enhanced Magnetic Resonance Imaging

Nephrogenic Fibrosing Dermopathy

China
First Affiliated Hospital of Zhejiang University
Jiangsu Aosaikang Pharmaceutical Co., Ltd.

Unknown

A Clinical Trial to Evaluate the Safety and Tolerability of Dexlansoprazole Injection in Healthy Chinese Adults（Part 2）

Safety Issues | Effect of Drugs

China
Jiangsu Simcere Pharmaceutical Co., Ltd.
The First People's Hospital of Lianyungang

Unknown

Continuous Endostar Infusion Combined With Radiotherapy in Patients With Brain Metastases

Brain Metastases

China
The First Affiliated Hospital of Zhengzhou University
BeiGene; Jiangsu Hengrui Pharmaceutical Co., Ltd.; RemeGen Co., Ltd.

Not yet recruiting

Study of Tislelizumab Combined With DisitamabVedotin and Pyrotinib Maleate in HER2-positive or Mutated Advanced Colorectal Cancer Who Failed Standard Therapy

HER2-positive or Mutated Advanced Colorectal Cancer
Third Affiliated Hospital, Sun Yat-Sen University
Jiangsu Hengrui Pharmaceutical Co., Ltd.

Recruiting

Carrelizumab (PD-1) Combined With Chemotherapy in Neoadjuvant Treatment of Locally Advanced Gastric Cancer

Locally Advanced Gastric Cancer

China
Zhou Chengzhi
Jiangsu Hengrui Pharmaceutical Co., Ltd.

Recruiting

Chemotherapy Combined With Camrelizumab and Apatinib in First-line Treatment of ES-SCLC

Extensive Stage Small Cell Lung Cancer

China
Women's Hospital School Of Medicine Zhejiang University
Jiangsu Hengrui Pharmaceutical Co., Ltd.

Unknown

Self-controlled Study Between 4-hour and 24-hour Delayed Radiographs in HSG Using OSCM

Infertility

China
First Affiliated Hospital, Sun Yat-Sen University
Jiangsu Simcere Pharmaceutical Co., Ltd.

Not yet recruiting

Edaravone Dexborneol for Treatment of Hypertensive Intracerebral Hemorrhage (ED-ICH)

Intracerebral Hemorrhage
Afﬁliated Hospital of North Sichuan Medical College
Jiangsu Simcere Pharmaceutical Co., Ltd.

Unknown

Endostar in Combination With Chemoradiotherapy in Patient With Advanced Non-small Cell Lung Cancer

Quality of Life

China
Chen Xiangmei
Jiangsu Suzhong Pharmaceutical Group Co., Ltd.

Unknown

Efficacy and Safety of Abelmoschus Manihot for IgA Nephropathy

IgA Nephropathy

China
Institute of Hematology & Blood Diseases Hospital...
Jiangsu Hengrui Pharmaceuticals Co.,Ltd

Recruiting

Herombopag Added to Cyclosporine in Non Severe Aplastic Anemia

Non Severe Aplastic Anemia | Untreated

China
Cancer Institute and Hospital, Chinese Academy...
Jiangsu Hansoh Pharmaceutical Co., Ltd.; GeneCast Biotechnology Co., Ltd.

Enrolling by invitation

Efficacy and Safety of Almonertinib Combined With or Without Chemotherapy as an Adjuvant Treatment for Stage II-IIIA Non-small Cell Lung Carcinoma Following Complete Tumour Resection (APEX)

Non-small Cell Lung Carcinoma

China
The First Affiliated Hospital with Nanjing Medical...
Jiangsu Hengrui Pharmaceutical Co., Ltd.

Recruiting

Camrelizumab Combined With Apatinib Mesylate and TACE in the Perioperative Treatment of Hepatocellular Carcinoma

Hepatocellular Carcinoma | Immunotherapy | Preoperative

China
The First Affiliated Hospital with Nanjing Medical...
Jiangsu Hengrui Pharmaceutical Co., Ltd.

Recruiting

Neoadjuvant Therapy of HAIC（GEMOX） Combined With Adebrelimab and Lenvatinib for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors

Intrahepatic Cholangiocarcinoma

China

Clinical Trials Sponsored by Jiangsu Topcel-KH Pharmaceutical Co., Ltd

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Uruguay

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations